COLLEGE OF PHARMACY
ACADEMIC REPORT FOR 2005-2006
1. 2005-2006 Highlights
a. Programmatic achievements

Initiatives in support of student engagement and success
After a year of extensive preparation described in last year’s report, the college was
visited by an evaluation team from the Accreditation Council of Pharmacy Education
(ACPE) in October of 2005. As an outcome, the professional doctor of pharmacy
(Pharm. D.) program was granted continuing accreditation in January 2006. The team
report was complimentary of our curriculum in general, the quality of our students,
faculty collegiality, the college’s commitment to students success, and enhanced staffing
in the college’s office of student affairs.
The accreditation team’s concerns focus on inadequate financial resources that result
in a smaller than desired faculty size, salaries that are markedly below market value, and
need for improved articulation between the Corvallis and Portland faculty and student
experiences. Progress in the college’s outcomes assessment process was cited, but
further information as to the overall assessment plan was requested. Several curricular
questions were raised, some of which are indirectly linked to our small faculty size and
articulation between campuses. An interim report will be submitted to ACPE in early
2007 and a focused on-site evaluation visit will occur in the fall of 2007.
In response to the accreditation findings, several immediate actions were taken. A
financial plan to significantly raise student tuition, with all new revenues to come directly
to the college, was approved by the Provost and the Vice President for Finance and
ultimately approved by the OUS Board for implementation in fall 2006. Further tuition
increases are proposed for autumn 2007 and 2008. In anticipation of the first phase of
new revenue, several faculty recruitments have been initiated and a plan has been
submitted to take the first steps toward addressing salary inequities. The following new
faculty have been hired:
Chrissa Kioussi, Ph. D. Assistant Professor, Pharmacology (replacement for Tony
Collins)
Joel Marrs, Pharm. D. Clinical Assistant Professor, Internal Medicine (replacement
for Nanette Bultemeier)
Jessina McGregor, Ph.D. Assistant Professor, Pharmacoepidemiology (new position)
Stacy Ramirez, Pharm. D. Clinical Assistant Professor, Community Practice (new
position)
College of Pharmacy. Page 1
Craig Williams, Pharm. D. Clinical Associate Professor, Internal Medicine
(replacement for Michelle Liedtke)
Vickie Staffelbach, MPA, Director of College Administration (replacement for
Evelyn Madison)
The following faculty searches are either in progress or will be initiated this summer:
Assistant Professor, Cardiology (new position)
Assistant Professor, Clinical Pharmacokinetics (1 or 2, replacements for Donna Belle
and Sandra Earle)
Assistant Professor, Medicinal Chemistry (replacement for Bill Gerwick). Note: an
offer has been made to Dr. Kerry McPhail, Ph.D., with an anticipated start date of
Sept. 2006)
Assistant Professor, Pharmacoeconomics/ Health Systems (1 or 2, replacements for
Lee Strandberg and Dan Touchette)
Clinical Assistant Professor, Community/ Ambulatory Practice (1 or 2, replacement
for Diane Nauman and one new position)
The move to the new building on the emerging OHSU riverfront campus late in 2006
will provide expanded classroom space, faculty offices, research space, and a more
positive atmosphere for both faculty and students in Portland. The new department chair
in Portland (Dr. Matthew Ito) is nearing the end of his first year at OSU and is committed
to promoting a greater sense of collegiality between the faculty and a welcoming
environment for students. Starting next academic year, members of the advising staff
will schedule regular hours to travel to Portland to assist students. A tentative plan is for
the Director of Alumni and Student Relations to relocate to Portland in July 2007, but
still come to the Corvallis campus once a week.
Tempering these positive steps are multiple faculty retirements and resignations on
both campuses (see above for replacement positions) that challenge our ability to
effectively teach several required course during the coming year, significantly higher
salaries and startup costs for the new hires, and the additional financial liability of over
$200,000 per year to pay for the higher cost of leased space in the new Portland facility.
As part of the college’s continuing commitment to academic excellence and in
response to the accreditation report, the curriculum committee rigorously reviewed the
first professional year curriculum during the last several months. Several course changes
have been approved by the faculty to improve sequencing of student learning.
Departmental retreats are scheduled for this summer to update departmental strategic
plans and further review the curriculum.
College of Pharmacy. Page 2
As discussed in detail in last year’s report, Senior Lecturer Ann Zweber was
appointed as the college’s director of assessment and chair of the assessment committee
in the fall of 2004. Her committee did considerable work to conduct surveys of the
students, faculty, and alumni in preparation for the accreditation site visit. The results of
these surveys were used as a guide by the curriculum committee in its deliberations to
modify or revise the professional program. The assessment committee continues to meet
frequently to develop a more comprehensive assessment plan as recommended by the
accreditation report.
The College of Pharmacy is committed to providing a welcoming atmosphere for its
students and staff, promoting professionalism, and ensuring student success. Numerous
events are scheduled throughout the year to bring students, faculty, and in some cases,
alumni, together and to continually instill the spirit of collegiality and professionalism.
Among the key events are:
A three day orientation program for incoming students before the start of fall quarter
A one day orientation program in Portland for third year professional students
The White Coat Ceremony in the fall for incoming students
An all college luau and pig roast in the in the fall
The Benefactor’s Reception in the fall for scholarship recipients to meet their donors
The Homecoming Brunch
The student recognition banquet and talent show in the spring
The College of Pharmacy graduation recognition ceremony

Major research/scholarship initiatives
During the 2005-06 fiscal year, College of Pharmacy faculty received 23 grants
totaling $1,468,457. As anticipated, this represents a decline from the previous fiscal
year, largely a function of the move of Professor William Gerwick to the University of
San Diego and secondarily a reflection of cutbacks in NIH funding at the national level.
We anticipate a steady growth in research funding over the next biennium as newly hired
junior faculty reach full productivity. Our goal is to reach $3 million in extramural
funding within the next two biennia.
See Appendix A: Grants and Contracts Awarded (listed alphabetically by faculty PI)
See Appendix B: Publications, Presentations, Awards, Travel, Service, and Other by
Faculty (listed alphabetically by faculty last name)
College of Pharmacy. Page 3
Listed below is an updated summary of the research initiatives within the college of
pharmacy. These initiatives remain fundamentally unchanged from last years’ report and
are closely aligned with the strategic plans of the university, the college, and the two
college departments. Specifically they address the OSU thematic area of realizing
fundamental contributions in the life sciences and optimizing the health and well-being of
the public. All new tenure track faculty hired in the last year or being recruited are
targeted to participate in these research focus areas.

Areas of research focus include:
o A multidisciplinary, translational infectious diseases research program has been
initiated with collaborations between the Departments of Pharmaceutical Sciences
and Pharmacy Practice and the Colleges of Pharmacy, Veterinary Medicine, and
Science. The emphasis on the Corvallis campus is on the discovery of novel naturally
occurring and semi-synthetic antibacterial molecules. Complementary investigations
are examining the creation of new vaccines and novel modes of vaccine delivery.
Early in 2006, Vice President for Research John Cassady convened a steering group
co-chaired by Luiz Bermudez (Veterinary Medicine) and Mark Zabriskie
(Pharmaceutical Sciences) to further define the mission of infectious disease research
at OSU and the potential for a broader drug discovery program beyond antibiotic
compounds. In turn, this group participated in development of a statewide signature
research center proposal entitled The Oregon Drug Discovery & Translational
Research Institute (ODDTRI). This is a joint proposal by Oregon Health & Science
University (OHSU), Oregon State University (OSU), Portland State University
(PSU), University of Oregon, and several Oregon-based biotechnology companies.
The institute will focus on the development and commercialization of therapeutics,
vaccines, and diagnostics for infectious diseases, neurodegenerative disorders, cancer
and other major problems affecting human health. A primary objective of this
proposal is to create a unique drug development consortium and facility that will
bridge the gaps between basic research, development and commercialization. This
proposal is currently under review by Oregon Innovation Council (Oregon InC), a
legislatively appointed research engine for the state.
Faculty: Mark Zabriskie, Ph.D., Professor of Medicinal Chemistry; Taifo Mahmud,
Ph.D., Assistant Professor of Medicinal Chemistry; Phil Proteau, Ph.D., Associate
Professor of Medicinal Chemistry; J. Fred Stevens, Ph.D., Assistant Professor of
Medicinal Chemistry; Patricia Flatt, Ph.D., Senior Research Assistant Professor of
Medicinal Chemistry; Kerry McPhail, Ph.D., Senior Research Assistant Professor of
Medicinal Chemistry; Xihou Yin, Ph.D., Senior Research Assistant Professor of
Medicinal Chemistry; Zhengrong Cui, Ph.D., Assistant Professor of Pharmaceutics
o A complementary component of the translational infectious diseases research
program is conducted by faculty on the Portland campus who conduct research to
identify mechanisms of antibiotic resistance, test novel dosing models in humans,
College of Pharmacy. Page 4
and perform pharmacoeconomic/cost effectiveness analysis of marketed
antibiotics. Current work includes studies of bacterial resistance to fluoroquinolones,
in various organisms, including Staphylococcus aureus, Pseudomonas aeruginosa,
and Streptococcus pneumoniae. This research includes collaborations with Corvallis
faculty and OHSU’s Molecular Medicine Institute. In addition, pharmacokinetic
modeling of various antimicrobials in special populations is studied as well as
assessment of pharmacists’ involvement in vaccine preventable diseases.
Faculty: George Allen, Pharm.D., Assistant Professor of Pharmacy Practice; David
Bearden, Pharm.D., Assistant Professor of Pharmacy Practice; Jessina McGregor, Ph.
D., Assistant Professor of Pharmacy Practice (Pharmacoepidemiology)
o A focus of the pharmacology section of the Department of Pharmaceutical Sciences is
to refine and expand our understanding of cell signaling as it pertains to activation of
cellular processing and control of gene expression. Development of genetically
modified small rodent models that facilitate our understanding of the significance of
alterations in organisms is an emphasis of these studies. Investigations include a
range of therapeutic concerns from ischemic diseases, cardiovascular function and
cancer. Small rodent models of disease currently available are targeted toward
mechanisms involved in for melanoma, leukemia and fetal development.
Faculty: Mark Leid, Ph.D., Professor of Pharmacology; Theresa Filtz, Ph.D.,
Assistant Professor of Pharmacology; Jane Ishmael, Ph.D., Assistant Professor of
Pharmacology; Arup Indra, Ph.D., Assistant Professor of Pharmacology; Chrissa
Kioussi, Ph.D., Assistant Professor of Pharmacology.
o Cardiovascular disease pharmacotherapy. Current activity in this group includes
clinical trials and pharmacokinetic, pharmacodynamics, metabolic, and
pharmacoeconomic/cost effectiveness studies of new and existing lipid lowering
drugs. Novel patient programs for improving patient care in patients with lipid
disorders and congestive heart failure are evaluated. Collaborative efforts have been
initiated with the OHSU cardiovascular division and Heart Research Center. The
hiring of several new faculty who will join the group in summer and fall of 2006 will
expand the research to include hypertension, heart failure and other chronic
cardiovascular diseases.
Faculty: Matthew K. Ito, Pharm.D., FCCP, BCPS, Professor and Chair; Terri
Bianco, Pharm.D., Associate Professor of Pharmacy Practice; Harleen Singh,
Pharm.D., Assistant Professor Pharmacy Practice; Joel Marrs, Pharm. D. Clinical
Assistant Professor of Pharmacy Practice; Craig Williams, Clinical Associate
Professor of Pharmacy Practice; Judi Low, BSN, Research Assistant
o Pharmaceutics faculty examine metabolic processes and mechanisms of drug
disposition that influence the therapeutic utility of drugs. Investigations explore
genomic influences on drug metabolism and how this may alter pharmacokinetic
models and drug toxicity.
College of Pharmacy. Page 5
Faculty: Rosita Proteau, Ph.D., Associate Professor of Pharmaceutics; J. Mark
Christensen, Ph.D., Associate Professor of Pharmaceutics
o Faculty on the Portland campus are developing a pharmacokinetics/
pharmacodynamics modeling and consulting program as a component of the OHSU
School of Medicine’s Pharmacokinetics Core. Areas of research are in infectious
diseases, nephrology, and oncology. Progress in this research area has been slowed
by the recent resignation of two faculty. New faculty searches are currently
underway.
Faculty: Myrna Munar, Pharm.D., BCPS, Associate Professor of Pharmacy
o The Drug Use Research and Management (DURM) Program now employs 5
clinical pharmacists and 2 support staff in Portland and Salem. They work with the
Oregon State Medical Assistance Program and Care Oregon to help shape state
policies for the cost-effective use of medications for low-income families. Their
research evaluates policies and methods to improve the use of prescription drugs.
This program is described further on page 7 of the report as part of the “major
outreach and engagement activities” section.
Faculty: Dean Haxby, Pharm.D., Associate Professor of Pharmacy Practice and
Director; Dan Hartung, Pharm.D., Research Associate; Ann Hamer, Pharm.D.,
Clinical Pharmacy Specialist; Rose-Ellen Hope, BS, Clinical Pharmacy Specialist;
Kathleen Ketchum, Pharm.D., Program Coordinator; Michele Koder, Pharm.D.,
Clinical Pharmacy Specialist; Naomi Pierce , Administrative Program Specialist;
Luke Middleton, Programmer.
o Pharmacoeconomics and biostatistics. These faculty conduct economic evaluations
of pharmaceutical and other therapies, assess practice patterns and subsequent
outcomes, and use large data bases (such as medical claims data bases) to develop
and test hypotheses about occurrence of disease and treatment patterns. Clinical areas
include oncology (brain tumors and chemoprotective agents), cardiology, diabetes,
neurology, osteoporosis, and women’s health. Progress in this research area has been
slowed by the recent resignation of two faculty. New faculty searches are currently
underway.
Faculty: Dale Kraemer, Ph.D., Associate Professor, Biostatistics,
Pharmacoeconomics and Outcomes Research
o The EMPOWER diabetes management demonstration and research project has
been launched in partnership with the directors of the human resource departments
from the cities of Eugene and Springfield and Lane County. This program is
designed to assess the impact of the community pharmacist’s education of patients on
diabetes control and healthcare utilization. To date 20 pharmacists have been trained
and 60 patients have been enrolled. Recruitment of other employers in Lane, Benton,
and Linn Counties is ongoing. Further description of the EMPOWER project are
College of Pharmacy. Page 6
found on page 8 of the report as part of the “major outreach and engagement
activities” section.
Faculty: Dale Kraemer, Ph.D., Associate Professor, Biostatistics,
Pharmacoeconomics and Outcomes Research; Terri Bianco, Pharm.D., Associate
Professor of Pharmacy Practice; Wayne Kradjan, Pharm.D., BCPS, Dean and
Professor of Pharmacy Practice; Stacy Ramirez, Pharm. D., Clinical Assistant
Professor; Judi Low, BSN, Research Assistant

Major outreach/engagement initiatives
Activities from the previous year’s report continue and are reproduced below with
only minor modifications.
The student pharmacy association (TRIAD) conducts a variety of community
outreach programs that include presentations on asthma, poison prevention, and
substance abuse avoidance to elementary, middle school, and high school students;
asthma, diabetes, and hypertension screening at pharmacies in the Corvallis and Portland
areas; and collaborates with pharmacists across the state to provide flu shots in local
pharmacies. The Phi Delta Chi fraternity partners with parish nurse organizations and
OSU County Extension Agents in Corvallis, Medford, and Portland to provide brown bag
medication reviews for senior citizens at local churches.
For the past ten years, the College of Pharmacy has supported the administration of
the state’s Medicaid program for low-income elderly, children, and disabled residents
under the provisions of a statewide interagency agreement with the Department of
Human Services (DHS), Office of Medical Assistance Programs (OMAP.) The resulting
Drug Use Research and Management (DURM) program has enhanced the safety,
effectiveness, and cost-efficiency of prescription drug use for Medicaid patients in
Oregon. A secondary contract exists with Care Oregon, a health maintenance
organization that serves Medicaid patients in the greater metropolitan Portland area.
Seven full-time OSU employees (five pharmacists and two support staff) comprise the
DURM team, headed by Dr. Dean Haxby, associate professor of pharmacy practice.
Their responsibilities include administering the Oregon Drug Use Review (DUR) Board
for DHS, evaluating drug utilization patterns among Oregon Health Plan (OHP)
members, analyzing and making recommendations to DHS on drug use policies, and
developing education strategies for Oregon Health Plan clinicians. In May 2004, DHS
and the DURM team launched two new prescriber education programs—the
Polypharmacy Review Program and the Plan Drug List (PDL) Education Initiative. The
OMAP contract is being re-written to transfer oversight to the Office Sponsored
Programs in the Research Office and to adjust the facilities and administration charges to
the off-campus rate of 26%. Gross revenues from this contact have grown steadily over
the last several years and are expected to approach $900,000 annually in the 2007 fiscal
year.
College of Pharmacy. Page 7
The college’s strategic plan states a goal to increase the visibility and service of the
college to the pharmacists and citizens of the state. Accordingly, development of a center
for innovative pharmacy practice and entrepreneurship is a major initiative in the
college’s strategic plan and its capital campaign agenda. As an initial step, several
members of the Department of Pharmacy Practice initiated a demonstration/ research
project in cooperation with the human resource directors for the cities of Eugene and
Springfield and Lane County. Additional employers in Benton, Lane, and Linn Counties
are being recruited with plans to expand to the Portland Metropolitan area in late 2007 or
early 2008. The primary goal of this research is to demonstrate the health related and
economic impacts of a pharmacist-delivered patient empowerment program (education
and medication therapy management) for diabetics. This project will assess the impact of
waiver of co-pays for diabetes-related utilization with and without a pharmacist directed
empowerment program. If this project is successful, it will be expanded to other parts of
the state and provide pharmacists’ care for additional chronic health problems.

National/International impact of programs and initiatives
The pharmaceutical sciences research (e.g., infectious diseases, drug discovery, and
genetically modified mouser modeling), the DURM Medicaid Program, and the
EMPOWER research project described above serve as examples to programs in other
states and help to enhance the college’s national reputation.
In collaboration with Mark Merickel in Extended Campus, the directors of pharmacy
for several large employers (Bi-Mart, Fred Meyer, Safeway, and Samaritan Health
Systems), and a business consultant from Linn Benton Community College, the college
developed a 9 module, 18 hour web-based continuing education course for practicing
pharmacists on human resource management. Marketing for this course to Oregon
employers, national pharmacy associations and all colleges of pharmacy in the US will
begin in August 2006.
b. Faculty recognition and awards
Angela Austin-Haney, Director of Student Services and Head Advisor is the Chair-Elect
for the Academic Advising Council for 2006-2007.
David Bearden was promoted to clinical associate professor
Gary DeLander served as President of the Rho Chi national pharmacy honorary society.
Gary DeLander was appointed to the 2006-07 Pharmacy College Application Service
(PharmCAS) National Advisory Panel.
Advisor, Nicole Kent, was given a certificate of merit for Outstanding New Advisor by
the National Academic Advising Association.
College of Pharmacy. Page 8
Matthew Ito was appointed to the Steering Committee for the Pacific Chapter of the
National Lipid Association (NLA).
Deanna Moretz was elected to serve as Secretary for OSHP Board of Directors 20062008, continuing to co-chair Educational Affairs Committee with Rob Rosenow, Dean at
Pacific University
Diane Nauman served as the pharmacist spokesperson in an educational video on head
lice treatment produced by Tec Labs of Albany, Oregon. Pharmacy footage for the video
was shot at a local independent pharmacy in Corvallis. The video will be distributed
nationally through PTA organizations to educate parents about head lice prevention and
treatment in children.
Diane Nauman was featured in the “Faces of OSU” promotional series at Oregon State
University.
Diane Nauman was invited to join the Oregon Patient Safety Commission - Prescription
Medication Safety Legislative Taskforce as a representative from the OSU College of
Pharmacy.
Dr. Rosita Proteau served as Chair of the Education Committee and Chair of the Minority
Initiatives Subcommittee of the Society of Toxicology and President of the Regional
Pacific Northwest Association of Toxicologists.
c. Student recognition and awards
Three OSU students were individually recognized at the American Pharmacists
Association-Academy of Students of Pharmacy (APhA-ASP) annual meeting in San
Francisco in April. Mike Fahey served as the APhA-ASP Region Seven Delegate and
was appointed to the APhA-ASP national Policy Committee. Mia Ha was elected as
APhA-ASP Region 7 Member at Large. Linda Wylie was the Oregon State University
Representative to APhA Patient Counseling Competition.
Three OSU students were individually recognized at the American Society of Health
Systems (ASHP) annual Student Society meeting in Las Vegas. Sarah Hilbert was
elected to the Leadership Development Subcommittee. Andrea Larkin and Wendy
Kagawa formed the team representing OSU at the ASHP Clinical Skills Competition.
Martha Kuhn received the United States Public Health Service Excellence in Public
Health Pharmacy Practice Award during the college’s graduation recognition ceremony
in June.
College of Pharmacy. Page 9
Strategic Plan Implementation
a. Focus for 2005-2006: Enhancing student success, increasing research and
outreach, and enhancing diversity and community

For each focus area, list the initiatives undertaken and the outcome at
the end of the year (include international dimensions within diversity)

Provide a brief self-assessment of the unit efforts in the three areas:
what worked; areas that need improvement; major barriers
Enhancing Student Success
Congruent with the university’s strategic plan, the college strives to pursue
excellence in professional and graduate education by providing a faculty, curriculum, and
learning environment that assures student access, retention, and success in the academic
programs and throughout their professional careers. The college has an ongoing
commitment to curricular review, systematic assessment, and enhancement. This
commitment was underscored during the past year as we prepared for and ultimately
received re-accreditation of the professional (Pharm. D.) degree program by the
Accreditation Council for Pharmacy Education (ACPE). See the “initiatives in the
support of teaching” section on page one in this report for an expanded description of this
area.
Increasing Research and Outreach
See section on “Major research/scholarship initiatives” above (pages 3-7)
See section on “Major outreach/engagement initiatives” above (pages 7-8)
Enhancing Diversity and Community.
As described in the 2005 report, surveys were sent to faculty, staff, current
students, and recent graduates as part of the accreditation self study to assess their
impressions of the quality of the education provided and the success of the college in
providing a nurturing environment. Several questions in each survey ask if faculty, staff,
and students treat each other equally regardless of gender, age, racial, or ethnic
background. The results of the surveys from faculty, staff, and recent graduates were
included in the 2005 diversity report and the accreditation self study. We will continue to
survey all future graduating cohorts approximately 1.5, 3, 5, and 10 years post
graduation.
The college advisors and the college’s director of alumni and student relations
continue to attend many health career fairs, including those aimed at students in the
Portland metropolitan area from high schools that have a high enrollment of
underrepresented students. We also partner with OHSU as part of their Comprehensive
College of Pharmacy. Page 10
Health Careers Opportunity Program (HCOP) grant which focuses on attracting
disadvantaged students and minorities to careers in the health sciences. Because
admission to the college requires a minimum of three years of prior college level
coursework, recruitment aimed at high school students has a relatively low yield. For the
last two years college advisors have visited the OSU cultural centers as an outreach to
students already on campus. The new director of alumni and student relations has
extensive background with the OSU Student Ambassadors program for the Colleges of
Agriculture and Forestry and brings specific knowledge of recruitment strategies for
Native American students to the college.
The College of Pharmacy faculty currently meets, but does not exceed, the
diversity of applicant pools of qualified prospective faculty members. We have been
successful in recruiting women and Asian faculty (three of five new faculty hired this
year are female) and have two faculty of Hispanic descent. We continue to be
unsuccessful in recruiting Black and Native American faculty. This is partly a factor of a
small nationwide pool of underrepresented minorities in pharmaceutical sciences
graduate training programs and an inability to compete with the monetary rewards of
pharmacy practice positions in the community setting for Pharm. D. trained students of
all backgrounds.
A new college diversity committee was formed in September 2006, chaired by
Dr. Rosita Proteau. The charge of this committee is to:
Develop a college-specific definition of diversity and corresponding diversity
mission, vision, and value statements. Help keep faculty, staff, and students
aware of programs developed by the university’s Office of Community and
Diversity. Attend to the university’s goals to: (1) attract diverse people including
faculty, staff, and students; (2) ensure a welcoming and inclusive atmosphere; (3)
assure that faculty, staff, and students demonstrate cultural sensitivity, including
inclusion of these topics in curricular offerings; and (4) create an atmosphere
where all can have a comfortable conversation about sensitive topics.
Each year, the committee will determine which issues they most want to
emphasize (e.g., student and faculty recruitment and retention; diversity and cultural
competency of the curriculum; faculty, staff, and student diversity and cultural
competency discussions; and/or diversity climate initiatives). This committee will also
work with the Outcomes Assessment Committee to coordinate periodic cultural
competency assessment of the faculty, staff, and students.
A minimum of three faculty, two staff, and two students comprise the
membership of this committee. Both academic departments and both campuses
(Corvallis and Portland) are represented. Membership of courtesy and/or affiliate faculty
is also encouraged.
Since January, the College of Pharmacy Diversity Committee met several times
via face to face meetings (using the college’s video conferencing network) and emails.
Dr. Terryl Ross met with the committee to discuss how he would like the college to
College of Pharmacy. Page 11
develop its Diversity Action Plan (DAP). Appendix C of this report is the current
working draft of the college’s DAP which is still undergoing revision. It will be sent to
the college’s constituency (administration, faculty, staff, and students) for their input later
this summer or at the beginning of fall quarter. Based upon the feedback received, the
final DAP report will be submitted to Dr. Ross in the fall.
Within the current draft, five planning priorities have been identified with an
estimated timeline and measurable objectives. These priorities are listed on page 19 of
this report in the section entitled “Proposed Priorities for 2006-2007. Because the college
of pharmacy does not have numerical values to truly assess retention of underrepresented
and marginalized communities within the college, the first priority focuses on assessing
the retention of the students, faculty and staff. The next three priorities focus on
activities within the College, while the last one focuses on external factors.
b.
Summarize major unit activities during 2005-2006 that helped promote one or
more of the five thematic areas
Oregon State University’s Strategic Plan for the 21st Century indicates an aspiration
to become a top 10 land grant institution. Among the five thematic focus areas of the
university is to “realize fundamental contributions in the life sciences and optimizing the
health and well being of the public.” As the strategic plan further states, “around these
existing strengths, we will build an integrated and novel program focused on the
prevention of disease, biomedical discovery and application, and the promotion of
health.” An emerging area of specific strength poised for substantial growth within the
health and life sciences theme relates to infectious disease research and drug discovery.
The College of Pharmacy plays a leading role in advancing this theme as described in the
section of this report entitled “major research and scholarship initiatives” (pages 3-6).
The College of Pharmacy is committed to expanding its research programs in bioorganic
chemistry and natural products (antibiotics) drug discovery as part of the statewide
signature research initiative in Drug Discovery and Translational Research.
c.
Summarize major accomplishments for 2005-2006 in support of the OSU Capital
Campaign
The college of Pharmacy has three major initiatives for the capital campaign that
parallel the university’s strategic plan and the mission of the college.

Scholarships. Enhancing student engagement and success requires making the
educational experience affordable and accessible. Endowed and current use scholarships,
and other funds for student enrichment through the Dean’s Fund for Excellence
contribute to goal to recruit Oregon’s best and brightest. Student support allows them to
focus on their studies and maximize their educational pursuits. In addition to increasing
annual fund contributions to scholarships, our goal is to obtain $1 million in new
scholarship endowments over the course of the capital campaign. During the past year,
College of Pharmacy. Page 12
three alumni established new named scholarships in amounts ranging from $25, 000 to
$30,000. Another individual pledged $100,000 for scholarships, though the terms of the
pledge have not been finalized.
a.
Drug Discovery. The drug discovery and infectious diseases research initiatives of the
college are described throughout this report. Current antibiotics are rapidly becoming
ineffective in the face of new diseases and resistant microorganisms. At the same time,
major drug companies are putting few resources toward developing new antibiotics. To
fill the gap, pharmacy researchers are working to find compounds that hold promise as
new antibiotics. An endowment of $1 million will help retain and attract faculty to
accelerate this mission. Current-use funds will purchase equipment and other supplies.
A pledge of $100,000 in support of this initiative is being pursued with an alumnus who
is a member of the OSU Foundation Board.

Progressive Pharmacy Practice and Entrepreneurship. Prescription drug therapies are a
key ingredient to preventing emergence of life threatening diseases and improving the
quality of life and productivity of patients with chronic illnesses. These life saving
interventions are of little value if patients are not able to afford needed medications or if
they do not take them correctly. Research has shown it is cost-effective and practical for a
pharmacist to be the primary patient care specialist for certain disease states. The
EMPOWER project in Lane County and the DURM Program described earlier in this
report (see pages 6 and 7) are the first steps of the college in developing innovative
practice models and entrepreneurship. As part of the capital campaign agenda for the
college, we propose to raise $1.5 million to establish an endowed program or
professorship for innovative pharmacy practice that will serve the needs of the
pharmacists of the state and improve the health of the citizens.
3. Other initiatives and their outcomes [e.g., Faculty/Staff Professional Development
Activities]
Primarily through the use of Foundation Funds, the college pays meeting registration and
travel expenses for junior faculty to attend professional meetings, especially if they are
presenting a paper or serving on a committee or task force. In particular, all faculty are
encouraged to attend the annual meeting of the American Association of Colleges of
Pharmacy. This organization offers programming aimed for new faculty orientation,
improving teaching, and leadership training.
As part of their start up package, new faculty are given funding to participate in the year
long grant writing workshop coordinated by the College of Health and Human Sciences.
Our past Director of College Administration, Evelyn Madison, wrote a proposal to the
Pharmacy Advisory Council requesting funds for Classified Staff Professional Development.
The proposal was approved and awarded $2500. To date the staff have taken on-line web
design courses, attended a technology security conference, a seminar on designing
publications, a communications seminar, and computer software courses. They have
College of Pharmacy. Page 13
purchased software from an audio conference on grammar, style and usage, and purchased
subscriptions to professional training magazines. The staff continue to take professional
development courses and seminars offered by Oregon State University’s Professional
Development program.
4. Scorecard
a. Performance on college-level metrics
The information in the tables on the next two pages was partially provided by the office of
institutional research, with other sections generated by the college of pharmacy.
College of Pharmacy. Page 14
College of Pharmacy
Metric
#
2002-03
Actual (AY/FY)
2003-04
2004-05
2005-06
College Targets
2007-08
Goal 1: Provide Outstanding Academic Programs
2004-05 Themes: Increase research and outreach
Increase diversity
1.1
1.2
1.3
1.4
Expenditures from Grants and Contracts, and Other Sources
Invention Disclosures
% of Faculty, Staff, and Students Comfortable with Climate for
Diversity
% of U.S. Minority Students of Total College Enrollment
$2,488,420
1
$1,962,967
4
$2,215,915
3
$1,294,772
Jan-07
$2,000,000
N/A
37
83.4
34.4
N/A
32.3
N/A
31.8
N/A
33
N/A
N/A
55
10
N/A
N/A
70
7
N/A
N/A
64
7
N/A
N/A
76
4
N/A
N/A
80
5
N/A
N/A
N/A
N/A
N/A
28.6 / 18.9
N/A
See separate table
79 / 447
6 / 55
30.3 / 19.1
99.2
separate table
83 / 810
8/ 77
14.5 / 14.4
100
separate table
83/ 896
3 / 49
TBA
100
separate table
84 / 975
5 / 48
90 / 1071 (Actual)
7
32 / $2,450,861
$315,670
18 / $1,650,761
$215,145
26 /
$2,316,698
$302,565
23 / $1,468,457
$483,626
-
Goal 2: Improve the Teaching and Learning Environment
2004-05 Themes: Improve student success and retention
Increase diversity
2.1
2.2
2.3
2.4
2.5
2.6
2.x.1
2.x.2
2.x.3
2.x.4
First Year Retention Rate (% Within College / % Within University)
6-Year Graduation Rate (% Within College / % Within University)
First Professional (PharmD) Degrees Awarded
Graduate Degrees Awarded
% of Seniors Participating in Student Engagement Activities / Number
of Respondents
Student Primary Major to Faculty FTE Ratio / Student Course to
Faculty FTE Ratio
Pass Rate on NAPLEX Board Exam (%)
PharmD (Doctor of Pharmacy) Total Graduation Rate (%)
First Professional Students Admitted / Applicants
Graduate Students Admitted / Applicants
98
Goal 3: Increase Revenues
3.1
3.2
Awards from Grants and Contracts (# / $)
Private Giving Revenue
"NA" -- Not Applicable: "TBA" -- Awaiting data requested from OSU unit.
College of Pharmacy. Page 15
Admission and Graduation Statistics
Entering Class year
Fall 1999
Fall 2000
Fall 2001
Fall 2002
Fall 2003
Size of
Class
69
78
72
79
83
Fall 2004
Fall 2005
83
85
Graduate in four years
Total Graduates
June 2003: 56 (81%)
June 2004: 66 (85%)
June 2005: 57 (79%)
June 2006: 66 (84%)
June 2007: 75 (90%)
(estimated)
June 2008
June 2009
63 (91%)
76 (97%)
68 (94%)
70 (89%
80 (96%) (estimated)
b. Leveraging resources

Initiatives to leverage state resources
Pharm. D. tuition was raised by $2, 500 per year for incoming Pharm. D. students
with a plan to further increase tuition by $1,000 per year for the next two academic
years. Revenues from the differential tuition will be returned directly to the college
to hire new faculty, address faculty salary inequities, enhance the student learning
experience, and pay for increased expenses associated with moving to the new
building in Portland.

Initiatives to improve administrative efficiencies
None to report
College of Pharmacy. Page 16
5. Assessment of your 2005-2006 Priorities
Provide a Brief assessment of your 2005-2006 priorities, including a self-assessment
of what worked, what did not, and lessons learned.
Activities during the past academic year mirrored the priorities articulated in
report entitled the “Top Four Initiatives for AY 2005-06” submitted in September of
2005. A copy of that document can be provided upon request. Briefly those initiatives
(and their sub-initiatives) included:
Achieving continued accreditation of the professional doctor of pharmacy
program
Continuing curricular review in response to the college assessment activities
Recruiting and hiring faculty to meet curricular needs and emerging research
priorities
Continuing support and growth of the research agenda around drug discovery,
infectious diseases, developing and refining models of disease and drug action
using models of genetically modified mice, cardiovascular diseases, and clinical
pharmacokinetics.
Continuing to serve the Oregon Medical Assistance Program (OMAP) and Care
Oregon through the college’s Drug Use Research and Management (DURM)
program.
Implementing the EMPOWER Project.
Developing a business plan for the College of Pharmacy to support new faculty
and improve faculty salaries
Actuating the college Diversity Plan Committee
Continuing development and implementation of the university campaign priority
goals for the college of pharmacy
As described in the body of this report, the college successfully addressed either
completely or partially all of the initiatives. The greatest accomplishments are achieving
continued re-accreditation of the professional program, gaining approval of a business
plan to increase tuition revenue to the college, developing a process to begin addressing
salary inequities, hiring of several new faculty, inclusion of the infectious disease
research program in the Oregon Drug Discovery and Translational Research Institute
signature research proposal, starting the EMPOWER project, and actuating the Diversity
Plan Committee.
College of Pharmacy. Page 17
Turnover of faculty has partially offset the gains achieved by the hiring of new
faculty. Research funding declined temporarily; there are delays in our cardiovascular,
pharmacoeconomics, and clinical pharmacokinetics research agendas; and we continue to
be challenged with identifying faculty to teach some of the Corvallis based courses. We
anticipate that each of these areas will improve during the 2006-07 academic year.
“Lessons learned” include the following:
1. We need to pay more attention to the process of transition from Corvallis to
Portland/OHSU to minimize student discomfort. As a result, the new Department
Chair in Portland is focused on the transition issue and student advisors are increasing
the amount of time that they spend on the Portland campus.
2. Continuing political realities at the state level require the need to continually develop
revenue streams that are independent of the state general education budget.
Substantial increases in professional student tuition are already being used as a
mechanism to achieve greater independence from state sources, but this has
limitations that could result in decreased overall recruitment. Of particular concern is
the effect on populations with restricted personal finances and a negative impact on
diversity goals. Increased funding in the form of grants and contracts, though
extremely important for the scholarly production of the college, are not readily
available to support the professional education and is also subject to limitations
because of shrinking federal budget allocations for science and health research. Other
means being pursued by the college to leverage state funding include joint faculty
appointments with pharmacy employers, a potential faculty hire to develop a revenuegenerating clinical pharmacokinetic/drug analysis service, and increased donor
support through the capital campaign.
3. The opening this fall of a new private school of pharmacy in Portland requires a reexamination and re-configuration of our marketing plan which is currently underway.
In the near future, close attention will be paid to application numbers and acceptance
rates of admitted students to assess and adjust for the potential impact of a second
choice for students in pharmacy schools in the state.
4. Changes at the National Institutes of Health in funding priorities and decreases in
overall real dollar funding levels required a re-examination of our R01 research
programs and strategies for retaining funding. As a result, hiring in both departments
has become more focused on building collaborative groups around common research
themes (e.g. the anti-infectives medicinal chemistry initiative and the mutant mouse
models of disease initiative in pharmacology). We will also see an increased reliance
on alternative funding opportunities such as the signature research center proposal
descried elsewhere in this report.
5. We need to increase collaborations with OHSU to provide more opportunities for
clinical experiences for our students, particularly in competition with the new private
College of Pharmacy. Page 18
school of pharmacy, and to develop avenues for more clinically relevant and NIHappealing health outcomes research
6. Retention of Pharmacy Practice faculty with clinical skills will continue to be
challenge as long as market forces continue to push pharmacists’ salaries that are
significantly higher than current faculty salaries. The recently approved equity
adjustment for pharmacy faculty partially addresses this issue, but is also important to
pursue faculty models that allow compensation from practice plans or as part of joint
appointments.
7. Similarly, retention and promotion of PhD faculty will be a challenge without
improved salary packages and without building a support network for collaborative
research within disciplines. Recent hires have been targeted to build areas of
common research strength.
8. There is a need to grow our academic programs to address the continuing shortage of
pharmacists while at the same time increasing efficiencies of instruction without
adversely affecting our current high quality of instruction in academic, clinical,
ethical and professional skills. Initial discussions to explore the possibilities of
developing branch campuses around the state, and using video and distance learning
technology to provide instruction with existing faculty, have begun. In addition to
potentially increasing tuition revenue, such an initiative may also improve the ability
of the college to recruit a more diverse student population and provide better
pharmacy service to more remote regions of Oregon.
9. Identification of barriers to recruitment of students, faculty and staff from
underrepresented populations will require a focused effort on the part of the entire
faculty with the coordination of the diversity committee and input from experts at the
University level. The development of the colleges Diversity Action Plan is the first
step in this process.
10. Global warming is beginning to wreak havoc with the building maintenance budget as
air conditioners and cold rooms fail every time it reaches 106°C in Corvallis.
6. Proposed Priorities for 2006-2007, particularly in the areas of

Student Engagement and Success
The curriculum will continue to be improved and refined as we review and implement
recommendations from the assessment surveys that were part of the accreditation selfstudy. Both departments are conducting retreats this summer to review their curriculum
with the intent to provide better articulation throughout three didactic years and with the
experiential programs.
Through the capital campaign we propose to double the value of endowed
scholarships over the next several years.
College of Pharmacy. Page 19
The college is scheduled for a ten year review of its graduate (MS and Ph.D.)
programs by the graduate school during the coming academic year. Surveys of past
graduates have been conducted and the policies and procedures manuals for the graduate
program are undergoing extensive revision. We anticipate continued approval of our
modestly sized, but outstanding graduate program.

Increasing research/scholarship and outreach
The college will continue to focus its research on infectious disease drug discovery,
translational research, use of genetically modified mice to model drug activity and
disease state outcomes, health care economics studies, and creation of innovative practice
models. Interdepartmental translational research projects in the areas of infectious
diseases and clinical pharmacokinetics will be expanded as new faculty are hired. In
particular we are excited about new funding that will come to OSU and the College of
Pharmacy if the Oregon Drug Discovery & Translational Research Institute (ODDTRI) is
approved by the Oregon Innovation Council (Oregon InC) for funding.
Our five year goal is to increase annual external funding to $3 million in external
funding, $2.5 million of which will come from PHS/NIH funding. Success in meeting
this goal is dependent on productivity of several newly hired faculty and our ability to
recruit new faculty as discussed in greater detail throughout this report.

Enhancing diversity and community
As indicated on page 15 and described in greater detail in Appendix C, the
College has identified five planning priorities addressing diversity and community
for the coming biennium.
1. Perform an assessment of retention of underrepresented and marginalized
populations among the students, faculty, and staff within the college so that
information can be obtained to establish future priorities focused on retention.
This can be performed beginning the 2006- 2007 academic year. The
measurable outcomes will be to have data by the end of the academic year.
2. Increase diversity competency efforts within the college by implementing a
variety of required faculty and staff training sessions that address an array of
diversity issues that will help them become culturally competent (e.g.,. Safe
Space training). This can be done yearly at regularly scheduled faculty/staff
meetings beginning 2006 – 2007 academic year. The measurable outcomes
will be to track attendance.
3. Establish events or documents to promote and recognize the significant
diversity that currently exists within the college. Promoting such events will
establish a welcoming climate that recognizes the importance of diversity.
One example of a current event is the Fall Luau during which the professional
College of Pharmacy. Page 20
students organize a celebration of Luau traditions, such as the pig roast. An
additional idea is to implement regularly scheduled pot-lucks for students,
faculty and staff to celebrate the different heritages by sharing ethnic foods.
This can be done regularly beginning 2006 – 2007 academic year. The
measurable outcome will be to track attendance.
4. Identify barriers (i.e., monetary, marketing, or other) in the recruitment of
students in the professional and graduate programs as well as faculty and staff
from underrepresented populations. Assure student, faculty and staff success
and retention by fostering a welcoming and inclusive, collaborative
environment. Assistance will need to be in place to develop surveys to
identify the barriers to recruitment and retention by each group. The
measurable outcomes for the i) students, professional and graduate, will be to
track progression through their respective programs; ii) faculty will be to track
promotion and tenure status as well as turnover (hiring and resignation); and
iii) staff will be to track promotion status as well as turnover (hiring and
resignation).
5. Establish faculty liaisons to provide “permanent” links to the cultural centers
such as OSU’s Black Cultural Center, Centro Cultural Cesar Chaves, Asian
and Pacific Cultural Center, and Native American Longhouse as well as to the
Women’s Center, Disabilities Services, and Pride Center. Set up a regular
system for faculty liaisons to report on diversity issues at quarterly faculty
meetings.

Capital Campaign
Priorities for the capital campaign are unchanged from 2005-06. The college’s
director of development resigned in July 2006. We look forward to rapid
identification of a new college development director and renewed emphasis on
visitations with alumni and other friends of the college.
College of Pharmacy. Page 21
Appendix A
Grants and Contracts
(Listed alphabetically by PI; College of Pharmacy faculty noted in bold font)
George Allen received an award from the Pharmacy Advisory Council for $5,000 to support
research by P4 students completing my elective research clerkship in 2006-2007.
Jim Ayres has received a one-year research grant for Formulation of Novel Dosage Forms from
Teva Pharmaceuticals USA in the amount of $80,000.
Zhengrong Cui received $29,968 from the Medical Research Foundation for a study titled
“Development of novel anthrax DNA vaccine for non-invasive immunization.”
Zhengrong Cui has been awarded three grants:
1. CUI, PI, Oregon Sea Grant, Development of a vaccine against fish mycobacteriosis,
$13,727
2. CUI, PI, OR-CAL Chemicals, Evaluation of the Anti-Tumor Activity of a proprietary
compound, $7,075
3. CUI, PI, Elsa U. Pardee Foundation, A Double-Stranded RNA-Adjuvanted, PeptideBased Vaccine for Cervical Cancer Immunotherapy, $59,183
Theresa Filtz received $20,000 from the Linus Pauling Institute as a pilot project grant titled
“Effects of hawthorn (Crataegus) plant extracts on cultured cardiomyocytes and endothelial
cells.”
The Pacific Mountain Affiliate Research Committee of the American Heart Association has
approved a proposal submitted by Theresa Filtz entitled: Determination of active principles of
Crataegus extract. The award will provide funding at the level of $66,000 per year over three
years.
Patty Flatt was awarded $30,000 from the MRF Committee for her grant entitled "Molecular
Evolution of the Paralomicin N-Glycosyltransferase For Use in Drug Design."
Patty Flatt was awarded $10,000 from the 2005-06 Spring General Research Fund for her
proposal entitled: “Characterization of Pyralomicin Halogenases for Use in Drug Design.”
William Gerwick received a second installment of $160,616 for his five-year subaward from the
Henry Ford Health System for a study titled, “Discovery and development of anticancer drugs
from cyanobacteria.” In addition, he received $307,636 from National Institute of Neurological
Disorders and Stroke for a four-year project titled “Neurotoxins from marine algae and
cyanobacteria.”
College of Pharmacy. Page 22
Ann Hamer, Dean Haxby, Dan Hartung and Luke Middleton are CoInvestigators/collaborators on a grant awarded by the NIMH to the Department of Human
Services, Office of Mental Health and Addiction Services entitled: Building the Foundation for
Evidence-Based Practices in Oregon. Principal Investigator: David Pollack, MD Total Funding:
$133,649
Jane Ishmael received $10,000 from the OSU General Research Fund for her proposal entitled:
A Role for Myosin II in NMDA Receptor Dynamics.
Peter Hsu an undergraduate in Dr. Ishmael's laboratory was successful in receiving an $1,800
URISC award for his project entitled: "Characterization of a previously undescribed calmodulin
binding site on the NMDA Receptor." The award will cover the cost Peter's salary in winter and
spring terms and provide him with money for laboratory supplies.
Dale Kraemer received $35,231 as a subaward of an NIH grant at OHSU. The project is titled,
“Statistical analysis of two compartment models to improve brain tumor therapy.”
Taifo Mahmud received the third installment ($233,024) of a four-year grant entitled
“Biosynthesis Approach to Novel Aminocyclitols” from the National Institutes of Health.
Neil Henricksen, working with advisors Phil Proteau and Theresa Filtz, has received a Howard
Hughes Medical Institute Summer Undergraduate Research Fellowship (coordinated at OSU by
Kevin Ahern in the Biochemistry Department) for his research project, “The Identification and
Characterization of the Cardioactive Principles in Hawthorn Extract”. Neil’s undergraduate
institution is Walla Walla College.
Fred Stevens received $20,000 from the Linus Pauling Institute as principle investigator for a
pilot project on enzymatic ascorbylation of oxidized lipids. The objective of the project is to
demonstrate the presence of an enzyme that catalyzes the conjugation reaction of vitamin C with
eletrophilic oxylipids in human hepatocytes.
Fred Stevens received $22,000 from a $240,297 USDA-CREES grant to study the effects of
meadowfoam glucosinolates and their degradation products on phase I and phase II metabolic
enzymes. Dr Russell Karow, Head of the Department of Crop and Soil Science, is the Principal
Investigator on this grant and Fred Stevens’ role is co-Principal Investigator.
The National Institutes of Health/National Center for Research Resources has awarded the OSU
campus Mass Spec Facility funding in the amount of $342,563 in response to the Shared
Instrumentation Grant application, “Hybrid Triple Quadrupole Linear Ion Trap Mass
Spectrometer.” Fred Stevens was the PI on the application.
Fred Stevens’ grant entitled "Oxidative Stress and Vitamin C Supplementation in Post-Surgery
Patients" has been approved for funding by the MRF Committee in the amount of $30,000.
College of Pharmacy. Page 23
Fred Stevens received the first installment ($309,368) of his five-year grant, entitled
“Ascorbylation of oxidized lipids and atherosclerosis” from the National Institutes of Health.
Cristobal Miranda is the co-principal investigator on this grant.
John Turner, working in the lab of Mark Zabriskie, has received an Undergraduate Research,
Innovation, Scholarship and Creativity award in the amount of $1,800 for his proposal titled
“Identification of Antibiotics Produced by Microorganisms from the Indonesian Black Water
Ecosystem.”
Xihou Yin was awarded $30.073.67 from the Medical Research Foundation of Oregon for
research involving biosynthetic gene clusters.
A $29,800 award was made from Research Equipment Reserve Fund, which is administered by
the OSU Research Office. The funds will go towards the purchase of a new High Performance
Liquid Chromatograph (HPLC), Mark Zabriskie, PI.
Mark Zabriskie received the third installment of $239,962 from the NIH for a grant titled
“Biosynthesis of Antitubercular Nonribosomal Peptides.”
College of Pharmacy. Page 24
Appendix B
Publications, Presentations, Awards, Travel, Service, and Other by Faculty
(Listed alphabetically by College of Pharmacy Faculty, noted in bold font)
Publications:
Bearden, DT, Holt T. State-wide impact of pharmacist-delivered adult influenza vaccinations.
Am J Prev Med 2005;29:450-2.
Garey KW, Neuhauser MM, Bearden, DT, Cannon JP, Lewis RE, Gentry LO, Kontoyiannis DP.
Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study. Mycoses
2006;49(3):226-31.
Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden, DT. Time to initiation
of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
Clin Infect Dis 2006;43:25-31.
Blanchard, D.L. and Zabriskie, T.M. Stereochemical control of capreomycidine biosynthesis,
46th Meeting of the American Society of Pharmacognosy, Corvallis, OR (July 2005)
Block John, Survey of Vitamins, Wiley’s Kirk-Othmer’s Encyclopedia of Chemical Technology,
5th ed., Article Online Posting Date: June 16, 2006.
Sowell J., Conway, H.M., Bruno R.S., Traber M.G., Frei B., Stevens, J.F., Ascorbylated 4hydroxy-2-nonenal as a potential biomarker of oxidative stress response,
Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences,
2005 Nov 15;827(1):139-45. Epub 2005 Jul 14. PMID: 16023898 [PubMed - in process]
Cui, Zhengrong, DNA Vaccine, Advances in Genetics, 2005, 54, 258-289.
Cui, Zhengrong, Qiu, Fu, Sloat, Brian R., Lecithin-based cationic nanoparticles as a potential
DNA delivery system, International Journal of Pharmaceutics, 313 (2006) 206-213.
Cui, Zhengrong, Dierling, Annie, Foldvari, Marianna, Non-Invasive Immunization on the Skin
Using DNA Vaccine, Current Drug Delivery, 2006, 3, 29-35.
Dierling, Annie M., Cui, Zhengrong, Targeting primaquine into liver using chylomicron
emulsions for potential vivax malaria therapy, International Journal of Pharmaceutics, 303
(2005) 143-152.
College of Pharmacy. Page 25
Fernandes, R.P.M., Phaosiri, C., Proteau, P.J., Mutation in the Flexible Loop of 1-Deoxy-Dxylulose 5-Phosphate Reductoisomerase Broadens Substrate Utilization, Archives of
Biochemistry and Biophysics, 2005, 444, 159-164.
Fernandes, R.P.M.; Proteau, P.J. Kinetic Characterization of Synechocystis sp. PCC6803 1Deoxy-D-xylulose 5-Phosphate Reductoisomerase Mutants, Biochimica et Biophysica Acta,
2006, 1764, 223-229.
Flatt, Patricia M., O'Connell, Susan J., McPhail, Kerry L., Zeller, Gloria, Willis, Christine L.,
Sherman, David H., Gerwick, William H, Characterization of the Initial Enzymatic Steps of
Barbamide Biosynthesis, Journal of Natural Products (2006), 69(6), 938-944.
Grochowski, L.L. and Zabriskie, T.M., Characterization of BlsM, a Nucleotide Hydrolase
Involved in Cytosine Production for the Biosynthesis of Blasticidin S., ChemBioChem 2006, 7,
957-964.
Metzger, D., Li M., Indra, A.K., Schuler, M. and Chambon, P., Conditional knockouts: Cre-Lox
systems, Cell Biology : A laboratory Handbook.(Elsevier Sc.) (2006) Chapter 53, 501-509.
LePage K.T., Ishmael, J.E., Low, C.M., Traynelis, S.F. and Murray, T.F., Differential binding
properties of [ 3H]dextrorphan and [ 3H]MK-801 in heterologously expressed NMDA receptors,
Neuropharmacology, (2005) 49, 1-16.
Ito, MK. Comment: supratherapeutic response to ezetimibe administered with cyclosporine. Ann
Pharmacother. 2005 Dec;39(12):2141. Epub 2005 Nov 15.
Gates R, Cookson T, Ito, M, Marcus D, Gifford A, Le TN, Nguyen CN. Therapeutic conversion
from fosinopril to benazepril at a Veterans Affairs medical center. Am J Health Syst Pharm.
2006 Jun 1;63(11):1066-8.
Kristin R. Gilmer Knight, Dale F. Kraemer, and Edward A. Neuwelt. Ototoxicity in Children
Receiving Platinum Chemotherapy: Underestimating a Commonly
Occurring Toxicity That May Influence Academic and Social Development. J Clin Oncol
2005;23:8588-8596.
Lieberman DA, Holub J, Eisen G, Kramer, D, Morris CD. Utilization of colonoscopy in the
United States: results from a national consortium. Gastrointest Endosc 2005;62:875-83.
Le, Uyen M., Cui, Zhengrong, Long-circulating gadolinium-encapsulated liposomes for
potential application in tumor neutron capture therapy, International Journal of Pharmaceutics,
312 (2006) 105-112.
Dickschat, JS; Bode, HB; Mahmud, T; Muller, R; Schulz, S., A novel type of geosmin
biosynthesis in myxobacteria, Journal of Organic Chemistry, 2005. Published online.
College of Pharmacy. Page 26
Mahmud, T., Wenzel, S.C., Wan, E., Wen, K.W., Bode, H.B., Baitatzis, N., Muller, R., A
novel biosynthetic pathway to isovaleryl-CoA in myxobacteria: The involvement of the
mevalonate pathway, ChemBioChem, 2005, 6:322.
Mahadevan, B., Mata, J. E., Albershardt, D. J., Stevens, J. F., Pereira, C. B., RodriguezProteau, R., Baird, W.M., The effects of red raspberry extract on PAH transport across Calu-3
cell monolayer, an in vitro cell model, International Journal Cancer Prevention, (2005) 2(2),
129-141.
Gafner, Stefan, Dietz, Birgit M., McPhail, Kerry L., Scott, Ian M., Glinski, Jan A., Russell,
Fiona E., McCollom, Megan M., Budzinski, Jason W., Foster, Brian C., Bergeron, Chantal,
Rhyu, Mee-Ra, Bolton, Judy L, Alkaloids from Eschscholzia californica and Their Capacity to
Inhibit Binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A Receptors in Vitro,
Journal of Natural Products (2006), 69(3), 432-435.
Torres-Mendoza, Daniel, Gonzalez, Jose, Ortega-Barria, Eduardo, Heller, Maria V., Capson,
Todd L., McPhail, Kerry, Gerwick, William H., Cubilla-Rios, Luis, Weakly Antimalarial
Flavonol Arabinofuranosides from Calycolpus warscewiczianus, Journal of Natural Products
(2006), 69(5), 826-828.
Bai, L.; Li, L.; Xu, H.; Minagawa, K.; Yu, Y.; Zhang, Y.; Floss, H.G.; Zhou, X.; Mahmud, T.;
Deng, Z. Functional Analysis of the Validamycin Biosynthetic Gene Cluster and Engineered
Production of Validoxylamine A, Chemistry & Biology., 2006, 13, 387-397.
Yu, Y., Bai, L., Minagawa, K., Jian, X., Li, L., Li, J., Chen, S., Cao, E., Mahmud, T., Floss,
H.G., Zhou, X., Deng, Z., A gene cluster encoding validamycin biosynthesis in Streptomyces
hygroscopicus var. jinggangensis 5008, Applied and Environmental Microbiology, 2005, 71,
5066-5076.
Munar, MY, Singh, H. Acute Renal Failure. In: Helms R, Quan DJ (ed): Textbook of
Therapeutics: Drug and Disease Management, 8th ed. Lippincott Williams & Wilkins, June
2006.
Rodriguez-Proteau, R., Mata, J. E., Miranda, C. L., Fan, Y., Brown, J. J., and Buhler, D. R.,
Plant polyphenols and multidrug resistance: Effects of dietary flavenoids on drug transporters in
Caco-2 and MDCKII-MDR1 cell transport models, Xenobiotica 36 (1): 41 – 58, 2006.
Simmons, T. Luke, McPhail, Kerry L., Ortega-Barria, Eduardo, Mooberry, Susan L.,
Gerwick, William H., Belamide A, A new antimitotic tetrapeptide from a Panamanian marine
cyanobacterium, Tetrahedron Letters, (2006), 47(20), 3387-3390.
Sloat, Brian R., Cui, Zhengrong, Evaluation of the immune response induced by a nasal
anthrax vaccine based on the protective antigen protein in anaesthetized and nonanaesthetized
mice, Journal of Pharmacy and Pharmacology, 2006, 58, 439-447.
College of Pharmacy. Page 27
Sloat, Brian R., Cui, Zhengrong, Strong Mucosal and Systemic Immunities Induced by Nasal
Immunization with Anthrax Protective Antigen Protein Incorporated in Liposome-ProtamineDNA Particles, Pharmaceutical Research, Volume 23, No. 2, February 2006, 262-269.
Haltli, B., Tan, Y., Magarvey, N.A., Wagenaar, M., Yin, X., Greenstein, M., Hucul, J. and
Zabriskie, T.M., Investigating -Hydroxyenduracididine Formation in the Biosynthesis of the
Mannopeptimcyins, Chemistry & Biology 2005, 12, 1163 – 1168.
Xu, J., Wan, E., Kim, C.J., Floss, H.G., Mahmud, T., Identification of Tailoring Genes
Involved in the Formation of the Polyketide Backbone of Rifamycin B by Amycolatopsis
mediterranei S699, Microbiology, 2005, 151, 2515-2528.
Wenzel, S.C., Meiser, P., Binz, T.M., Mahmud,T., Müller, R., Nonribosomal Peptide
Biosynthesis: Point Mutations and Module Skipping Lead to Chemical Diversity, Angewandte
Chemie International Edition, 2006, 45, 2296-2301
Woo, Y-H., Fernandes, R.P.M., Proteau, P.J., Evaluation of Fosmidomycin Analogs as
Inhibitors of the Synechocystis sp. PCC6803 1-Deoxy-D-xylulose 5-Phosphate
Reductoisomerase, Bioorganic and Medicinal Chemistry, 2006, 14, 2375-2385.
Xiong, Y., Wu, X., Mahmud, T., A homolog of Mycobacterium tuberculosis PapA5 protein,
RifOrf20, is an acetyltransferase involved in the biosynthesis of antitubercular drug bifamycin B
by Amycolatopsis mediterranei S699, ChemBioChem, 2005. 6:834.
Giri, S., Idle, J.R., Chen, C., Zabriskie, T.M., Krausz, K.W. and Gonzalez, F.J., A Metabolomic
Approach to the Metabolism of the Areca Nut Alkaloids Arecoline and Aracaidine in the Mouse,
Chemical Research in Toxicology, 2006, 818-827
Rachid, S., Krug, D., Kunze, B., Kochems, I., Scharfe, M., Zabriskie, T.M., Blöcker, H. and
Müller, R., Molecular and biochemical studies of chondramide formation - highly cytotoxic
natural products from Chondromyces crocatus Cm c5, Chemistry & Biology, 2006, 667-681.
Ritacco, F.V., Graziani, E.I., Summers, M.Y., Zabriskie, T.M., Yu, K., Bernan, V.S., Carter,
G.T. and Greenstein, M., Production of Novel Rapamycin Analogs by Precursor-directed
Biosynthesis, Applied and Environmental Microbiology, 2005, 71, 1971-1976.
Presentations:
Aebi, C. Chemotherapy induced nausea and vomiting. Oregon State Pharmacists Association
Spring CE Meeting, Portland, OR, March 5, 2006 and Medford, OR, April 9, 2006.
Allen, GP, Bierman BC. Investigation of the mutant prevention concentration of linezolid for
Enterococcus faecalis, Enterococcus faecium, and Staphylococcus aureus. American College of
Clinical Pharmacy Spring Practice and Research Forum, Monterey, CA, April 2006.
College of Pharmacy. Page 28
Bearden, DT, Earle SB, McConnell DB, Belle DJ, Kohlhepp SJ. Pharmacokinetics of
meropenem in extreme obesity. 45th Interscience Conference on Antimicrobial Agents and
Chemotherapy. Washington DC, December 2005.
Bearden, DT presented a seminar, entitled ‘“A weighting game: Antibiotic dosing in obesity” at
the Oregon Society of Health-System Pharmacists Annual Seminar in Sun River, Oregon, April
28-30, 2006.
Garey, KW, Reg, M, Pai, MP, Mingo DE, Suda KJ, Turpin RS, Bearden, DT. Time until
initiation of fluconazole therapy impacts mortality in patients with candidemia: A multiinstitutional study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Washington DC, December 2005.
Conway, H.M., Gordillo, R., Kesinger, N.G., Sowell, J., Miranda, C.L., Stevens, J.F. (2006).
Ascorbylation and Glutathionylation of Lipid Peroxidation Products as Potential Biomarkers of
Oxidative Stress Response. 54th American Society for Mass Spectrometry Conference on Mass
Spectrometry and Allied Topics, Seattle, Washington, May 28-June 1 (poster).
Fan, Y. and Rodriguez-Proteau, R. “Effects of ketoconazole on multidrug resistant-mediated
transport in Caco-2 and MDCKII-MDR1 drug transport models” Toxicological Sciences, The
Toxicologist, 80 (1-S), Abstract #1686. Society of Toxicology Annual Meeting, San Diego, CA,
2006.
Fei, X., Yin, X. and Zabriskie, T.M. Studies on three proteins in viomycin biosynthesis. 46th
Meeting of the American Society of Pharmacognosy, Corvallis, OR (July 2005)
Flatt, P.M.; Wu, X.; Mahmud, T. Isolation and Characterization of the Pyralomicin
Biosynthetic Gene Cluster. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006,
Pack Forest Research Station, Eatonville, WA (Poster Presentation)
Ishmael, J. Regulation of NMDA receptor function by Myosin II Department of Physiology
and Pharmacology, College of Veterinary Medicine at the University of Georgia in Athens,
Georgia (invited speaker)
Ishmael, J; Bajaj,G.; Yang, J. and Amparan, D. Direct Interaction of a Myosin Light Chain
with the Membrane-proximal Region of NMDA Receptor Subunits. Annual Meeting of the
Society for Neuroscience, November 2005, Washington D.C. (Poster)
Cheung RJ, Ito, MK, Henry RR. Is the cholesterol lowering response to a statin and a
cholesterol absorption inhibitor inversely related? A prospective, randomized, cross-over design
study. Poster presentation at the 2005 Annual Meeting of the American College of Clinical
Pharmacy. San Francisco, CA. October 26, 2005
Ito, MK. Practical Aspects of Lipid Management. Oral presentation at the 2005 Annual
Meeting of the American College of Clinical Pharmacy. San Francisco, CA. October 22, 2005
College of Pharmacy. Page 29
Ito, MK. What if Cholesterol Lowering is Just Part of the Story? Oral presentation at the 2005
Annual Meeting of the American College of Clinical Pharmacy. San Francisco, CA. October
25, 2005.
Ito MK. New Data Sets for Statins, Nonstatins, and Diabetes for LDL-C Lowering. Pharm-Med
Updates meeting, Los Angeles, CA - May 11, 2006
Ito MK, Aldridge VE, Howard JJ, Gupta EK, Johns ST, Wong JK. “Effects of an Encapsulated
Formulation of Pravastatin on Plasminogen Activator Inhibitor-1 in Patients with Human
Immunodeficiency Virus Infection.” 7th Annual Conference on Arteriosclerosis, Thrombosis
and Vascular Biology, Denver, CO - April 29, 2006.
Kesinger, N.G., Morré, J., Machado, S., Stevens, J.F. (2006). LC-MS/MS Analysis of
Glucosinolates and their Enzymatic Degradation Products in Meadowfoam Seed Meal. 54th
American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics,
Seattle, Washington, May 28-June 1 (poster).
Linares R and Zweber A, Home Testing Kits, Oregon State Pharmacists Association Spring CE
Meeting, Portland, OR, March 5, 2006 and Medford, OR, April 9, 2006
Mahmud, T., Biosynthesis of Microbial-Derived Aminocyclitol Family of Natural Products.
231st American Chemical Society (ACS) National Meeting, March 26-March 30, 2006, Atlanta,
Georgia. (Invited Oral Presentation at the Ernest Guenther Award Symposium).
Minagawa, K.; Zhang, Y.; Ito, T.; Bai, L.; Deng, Z.; Mahmud, T. Functional Analysis of the
Cyclitol Kinase ValC Involved in Validamycin A Biosynthesis. Volcano Conference in
Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station, Eatonville, WA (Poster
Presentation)
Miranda, C.L., Chung, W.G., Li, H.J., Stevens, J.F., Maier, C.S. (2006). A Proteomic
Approach for Evaluating the Effects of Proanthocyanidins on Rotenone-Induced Toxicity in SHSY5Y Neuroblastoma Cells. 54th American Society for Mass Spectrometry Conference on Mass
Spectrometry and Allied Topics, Seattle, Washington, May 28-June 1 (poster).
Moretz, D. "Pharmacy Perspectives on Pain Management" Oral presentation at the 2005
Oregon Nurses Association Meeting. Salem, OR October 26, 2005
Moretz, D. "Preceptor Workshop - The Art of Evaluating Students" Moderator and speaker.
Portland, OR November 1, 2005
Moretz, D. presented "Perspectives on Pain Management" on February 19, for the Lane County
Pharmaceutical Association, on February 22 to the Oregon Nursing Association, and on March
15 at the SAIF Pain Management Conference 2006.
Moretz, D. presented "Precepting and Evaluating Clerkship Students" on February 25, at the
OSHP Winter Festival
College of Pharmacy. Page 30
Moretz, D. presented “Pharmacy Perspectives on Pain Management" date and site?
"Novel Tobramycin Dosing in Hemodialysis to Minimize Toxicity" Osama Mohamed, PhD,
Myrna Y. Munar, PharmD, Sandra B. Earle, PharmD, James W. Ayres, PhD, William M.
Bennett, MD, Suzanne Watnick, MD, Ihab Wahba, MD. Poster presentation at the American
Society of Nephrology Annual Meeting, November 11, 2005, Philadelphia, PA
Nauman, D: “Cross-Practice Comparison of Preceptor Evaluations of Student Professionalism
and Ethical Conduct During Early Experiential Rotations” abstract accepted as a poster
presentation at AACP 2006 Annual Meeting in San Diego, CA in July 2006.
Nauman, D: Developed an Immunization Delivery Certification Program for the OSU College
of Pharmacy. Ms. Nauman presented a program overview to the members of the Oregon Board
of Pharmacy at their meeting in February 2006.
Sheeba,V.; Flatt, P.M.; Mahmud, T. Overexpression and Enzymatic Study of
Nucleotidylyltransferases from the Validamycin and Acarbose Gene Clusters. Volcano
Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station,
Eatonville, WA (Poster Presentation)
Han, B., Stevens, J.F., Maier, C.S. (2006). Carbonylated Proteins Probed by a HydrazideFunctionalized Isotope-Coded Affinity Tag (HICAT). 54th American Society for Mass
Spectrometry Conference on Mass Spectrometry and Allied Topics, Seattle, Washington, May
28-June 1 (poster).
Wan, E.; Mahmud, T. Mutagenetic Approaches to Novel Myxalamids in Stigmatella
aurantiaca. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest
Research Station, Eatonville, WA (Poster Presentation)
Wu, X.; Flatt, P.M.; Mahmud, T. Biosynthetic Studies on the Antitumor Agent Cetoniacytone
A. Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research
Station, Eatonville, WA (Oral Presentation)
Xiong, Y.; Mahmud, T. Genetic and Synthetic Approaches to New Antitubercular Drugs.
Volcano Conference in Bioorganic Chemistry, Feb. 24-26, 2006, Pack Forest Research Station,
Eatonville, WA (Poster Presentation)
Xiong, Y.; Mahmud, T. Genetic and Combinatorial Synthetic Aproaches To Novel Rifamycin
Analogs. Gordon Research Conference on New Antibacterial Drug Discovery and Development,
March 5-March 10, 2006, Ventura, California. (Poster Presentation)
Yao, Q. and Proteau, P.J. Cloning the Diterpene Gene Cluster for the Fungal Antibiotic
Pleuromutilin, Volcano Conference in Bioorganic Chemistry, Pack Forest, WA, February 24-26,
2006, (Poster presentation)
College of Pharmacy. Page 31
Yin, X. Tan, T., Zhang, L. and Zabriskie, T.M. Cloning, sequence and initial characterization
of the enduracidin biosynthetic gene cluster. Gordon Research Conference on New Antibiotic
Development, Ventura, CA (March 2006)
Brooks AM and Zweber A, Increasing Cultural Competency and Health Literacy, American
Pharmacists Association Annual Meeting and Exposition, San Francisco, CA, March 18, 2006
Yin, X. and Zabriskie, T.M. Molecular genetic studies on the viomycin biosynthesis genes. 46th
Meeting of the American Society of Pharmacognosy, Corvallis, OR (July 2005)
Zabriskie, T.M., Portland State University, Department of Chemistry, Portland, OR (February)
Precursor amino acid formation and post-assembly tailoring associated with nonribosomal
peptide antibiotic biosynthesis in Streptomyces spp.
Zweber A and Watt M, Oregon Board of Pharmacy Technician Update, Oregon State
Pharmacists Association Spring CE Meeting, Portland, OR, March 5, 2006 and Medford, OR,
April 9, 2006
Zweber A and Dowling B, Assessing English Language Proficiency during the Interview
Process, American Association of Colleges of Pharmacy Interim Meeting, San Antonio, TX,
March 1, 2006
Zweber, A, OTCs on the Horizon, APhA’s Self-Care Institute Annual Meeting, Baltimore, MD,
June 24, 2006.
Campbell C and Zweber A, Panel on Pharmacy Refusals, OSU Women's Center, Corvallis, OR,
May 4, 2006.
Awards/Certifications:
Ann Hamer is now a Board Certified in Psychopharmacotherapy by the Board of
Pharmaceutical Specialties.
Moretz D Received OSHP President's Award for sustained contribution and leadership to
OSHP.
Moretz D. has received BCPS recertification for 2006-2013
Travel and Professional Service:
John Block attended the following meetings of the National Association of Boards of
Pharmacy’s Foreign Pharmacy Graduate Equivalency Examination Committee
January 9 - Chicago
Examination Blueprint Revision (1-day meeting)
College of Pharmacy. Page 32
March 23 – 26 San Diego
Review questions for the June examination
April 27 – 30 Chicago
Medicinal Chemist Facilitator at an item writing session where faculty write questions for
the examination.
Mark Christensen was featured in an article entitled, “Soap, water: Magic potion to stop poison
plant itch” in the March 16 edition of OSU This Week. Dr. Christensen was interviewed for his
insights in treating and preventing poison oak and poison ivy.
Gary DeLander presented as part of a panel entitled Paws, People and Pills: Veterinary, Public
Health and Pharmacy. The panel focused on non-academic considerations in admissions to
professional schools and was part of the annual meeting of the National Association of Advisors
for Health Professions meeting in Portland on June 28, 2006.
Gary DeLander joined Ann Zweber and Wayne Kradjan in attending the interim AACP
meeting. The meeting was focused largely on issues related to diversity.
Gary DeLander, Ann Zweber, Diane Nauman, and Matt Ito attended a national AACP retreat
to examine opportunities and alternatives to enhance experiential education.
Theresa Filtz has been appointed Secretary/Treasurer-Elect for the Molecular Pharmacology
division of ASPET.
Graduate students in the College met to present their research at the 2006 College of Pharmacy
Research Retreat, April 7-8, 2006, Salishan Spa and Golf Resort, Gleneden Beach, Oregon, as
previously reported in the research retreat program.
Jane Ishmael was an invited speaker at the March meeting of the local Migraine and Headache
Support Group in Corvallis where she discussed, "Migraine versus Chronic Daily Headache."
The Board of Directors of the American Society of Pharmacognosy Foundation identified Taifo
Mahmud as a recipient of this year’s Matt Suffness Award, in recognition of his research in the
area of natural products. The award was presented at the 47th Annual Meeting of the ASP annual
banquet on August 9, 2006, in Washington D.C.
Taifo Mahmud was initiated as a member of the Honor Society of Phi Kappa Phi, Oregon State
University Chapter on May 4, 2006.
Taifo Mahmud attended the Gordon Research Conference on New Antibacterial Drug
Discovery and Development, March 5-March 10, 2006, Ventura, California.
Taifo Mahmud attended the 231st American Chemical Society (ACS) National Meeting, March
26-March 30, 2006, Atlanta, Georgia.
College of Pharmacy. Page 33
Kerry McPhail attended the Gordon Research Conference on Marine Natural Products February
26-March 3, 2006.
Phil Proteau, Taifo Mahmud, Patty Flatt and several graduate students in Medicinal
Chemistry and Natural Products attended the annual Volcano Conference at Pack Forest,
Washington.
Rosita Proteau and Ying Fan attended the Society of Toxicology (SOT) 2006 Annual meeting
in San Diego. Dr. R. Proteau has served on SOT’s Education Committee for the past three years
and is now the Chair of the Education Committee. The Education Committee is responsible for
numerous activities at the annual meeting which include the K-12 Paracelsus goes to School
Workshop, Minority Undergraduate Program, Novartis Graduate Fellowship Interviews, Pfizer
Undergraduate Travel Awards, and the Distance Education Symposium. Dr. Proteau also served
as the “Final Manuscript Judge” for the Carl C. Smith Student Awards from SOT’s Mechanisms
Specialty Section as well as serving as SOT’s Regional Chapter President of the Pacific
Northwest Association of Toxicologists.
Fred Stevens presented a seminar, entitled ‘Ascorbylation of natural products and oxidized
lipids’, at the University of Illinois, Chicago (UIC), on April 28, 2006. This seminar was hosted
by the Department of Medicinal Chemistry and Pharmacognosy at UIC.
Fred Stevens presented the 2006 John Bauers lecture, entitled ‘Xanthohumol and other beer
flavonoids: To your good health!?’ in Portland on May 7, 2006. This lecture was hosted by the
Society of Physicians for Wine and Health.
Patents Awarded:
United States:
Number 6,964,782, Stable hydrogen peroxide compositions, products and
methods of use. Granted November 15, 2005.
Inventors:
Robert Lee Smith, Steven Dale Smith, Wendy S. Langley, Vernon W.
Smith, John Mark Christensen.
College of Pharmacy. Page 34
Appendix C
Diversity Action Plan
College of Pharmacy
Sent as separate attachment
College of Pharmacy. Page 35